Yi-Kai Lo CEO

ANEUVO's ExaStim® (Los Angeles, California) is a portable, wireless, multi-channel spinal stimulation system that delivers clinician-adjusted, patient-specific, non-invasive neuromodulation in clinical and home settings. In Europe, ExaStim is CE marked to improve upper-extremity motor function in adults with spinal cord injury across injury stages and subtypes. In the U.S., it is FDA 510(k) cleared to improve hand sensation and strength in adults with chronic incomplete SCI when used in conjunction with functional task practice.

Therapeutic: Neuromodulation-Neurostimulation

Frank Cheng CEO

In collaboration with Cedars-Sinai Medical Center, BlackLight Surgical (Los Angeles, CA) developed an optical imaging and autofluorescence platform that gives surgeons a real-time view of cancer—in the body and on excised tissue—with no dyes or drugs. The technology was awarded FDA Breakthrough Device Designation. The payoff: better surgical outcomes with no cancer left behind, and instant point-of-care answers without waiting for pathology. BlackLight's vision reaches beyond oncology—toward real-time tissue viability assessment for organ transplant and wound/ulcer care, redefining how clinicians see living tissue.

Therapeutic: Surgery; Oncology

Ida Good CEO

Cerevia Neurosciences (Castro Valley, California USA) is developing the Ladybug™ Sanctuary, a clinic-based, NeuroAI-enabled, fMRI-guided closed-loop network neuromodulation platform for Alzheimer’s dementia. Patient and platform digital twins personalize targeting, stimulation, and treatment adaptation. Each session generates longitudinal imaging, treatment, and outcomes data, transforming therapy into intelligence that can improve care, support biomarker discovery, accelerate research, and enable expansion into additional neurologic indications.

Therapeutic: Neuromodulation-Neurostimulation; Digital Health, Women's Health

Mark Alley CEO

Cipher Surgical (Chantilly, VA) is a medical device company established in 2010 and launched the OpClear platform for use in laparoscopic procedures to provide continuous intra-abdominal vision to the surgical team, maintaining a surgical flow associated with fewer surgical errors and shorter operating times. The OpClear platform uses automated CO2 flow and on-demand saline lens wash, minimizing the need for scope removal during a procedure and addressing many of the frustrations associated with visual obstructions. This rapidly clears larger visual obstructions such as fogging, misting and blood or particles from energy plumes to provide continuous vision throughout each procedure.

Therapeutic: Surgery

Bhaskar Ramamurthy CEO

Cordance Medical, based in Mountain View, California, develops a portable, non-invasive focused ultrasound platform for precision medicine in the brain. Its proprietary NeuroAccess device, a wearable cap with integrated transducers used with microbubbles, safely opens the blood-brain barrier in an outpatient setting without MRI-suite constraints or disfiguring preparation. This lets tumor biomarkers enter the bloodstream for simple blood-draw diagnosis (SonoBiopsy), its beachhead application in brain cancer, and allows targeted delivery of therapeutics to the brain (SonoScript).

Therapeutic: Precision Medicine; Neurology

Jodi Akin Chair

ChordArt (Radolfzell, Germany) is a transseptal chordal-replacement system designed around the mitral valve's native physiologic anatomy. Using a conventional transseptal access approach already familiar from TEER procedures, it is involves five steps from access to deployment:

• Fixed-length, pre-loaded implant removes intraprocedural knotting and length adjustment, reducing procedural complexity.

• No tensioning of the leaflet, and correct length can be reconfirmed before final deployment – supporting a favorable safety profile.

• Operator-independent and scalable, with an intuitive, translatable procedure and fast operator learning curve.

• Low-risk clinical profile broadens the eligible patient population and preserves future treatment options rather than foreclosing them.

Therapeutic: Cardiovascular; Valvular heart disease

Marcin Golebicki CEO

EBAMed's (Geneva, Switzerland) mission is to enable safe and effective STereotactic Arrhythmia Radioablation (STAR) procedures for the treatment of cardiac patients. The company has developed a unique gating system powered by a proprietary AI software to ensure precise dose delivery while sparing non-target tissues. This solution is an accessory to radiotherapy (RT) machines, and it is designed to actively manage cardiac motion during STAR procedures by synchronizing beam delivery with both cardiac and respiratory motion.

Therapeutic: Imaging; Non-invasive Cardiac Radioablation

Boris Schmitt CEO

Coming soon.

Therapeutic: Coming soon.

Mike Connolly CEO

Healionics (Seattle, WA, USA) is developing safer, more reliable means of bloodstream access to support life-saving dialysis therapy in kidney failure patients. Its STARgraft AV graft shows excellent clinical resistance to both occlusion and infection -- the two primary causes of failure in on-market grafts. The company also has a diverse product pipeline leveraging its core biomaterial technology which can inhibit scar tissue encapsulation and infection to improve performance of a wide range of other implantable devices and facilitate creation of new ones.

Therapeutic: Cardiovascular; Dialysis access devices, Vascular Surgery, Biomaterials

Richard van de Wateringen CEO

IPD (Leiden, The Netherlands) is developing a medical device using induction heating technology to treat Prosthetic Joint Infections during the standard of care. By using induction technology, the implant is heated while still inside the patient- eliminating bacteria and biofilm on the implant and ultimately curing the infection.

Therapeutic: Infection Control

Joshua Reicher CEO

IMVARIA (Berkeley, CA, USA) is a leading applied clinical AI company delivering FDA-cleared services into everyday practice through a unique centralized model. We operate a CMS-approved offering in alignment with the new Software-as-a-Medical-Service (SaMS) pathway, through rapid-adoption, zero integration workflows. The platform's leading assets are Fibresolve and ScreenDx, both in high impact lung disease, driving accelerating national adoption and major patient impact across health systems, payers, and pharma partners. Our pipeline extends this model into multiple areas in oncology, with additional services in active development.

Therapeutic: Artificial Intelligence; Pulmonary

Andrew Holman Founder & CEO

Inmedix, Inc. (Seattle) makes the CloudHRV® System, an FDA-cleared, medical-grade heart rate variability diagnostic. In a 5-minute in-office test, it measures the sympathetic ("fight-or-flight") and parasympathetic ("rest and restore") parts of the autonomic nervous system. This gives clinicians an objective view of immuno-autonomic function in autoimmune diseases such as rheumatoid arthritis.

Therapeutic: Diagnostics; Medical Device

Gregg Smith  CEO

Lite Run (St. Paul, MN) is a medical technology company transforming patient mobility and rehabilitation. Its FDA-registered anti-gravity mobilization system uses patented pneumatic Exosuits to safely support and unweight patients during standing and walking. Unlike traditional harness-based systems, Lite Run is mobile, comfortable, and designed for use by a single clinician. The technology helps healthcare providers mobilize patients earlier, improve therapy efficiency, reduce physical strain on staff, and support better functional recovery.

Therapeutic: Mobility In-Patient and Home

Jorge Ferrer Chief Scientific Officer

Lumicell (Waltham, MA, USA) is a commercial-stage company transforming cancer surgery through real-time, fluorescence-guided tumor detection. Its FDA-approved LumiSystem™, combining the LUMISIGHT™ (pegulicianine) plus the Lumicell Direct Visualization System, is the first and only technology enabling surgeons to detect residual cancer directly inside the breast lumpectomy cavity during surgery. Backed by established Medicare and commercial reimbursement, LumiSystem is gaining momentum with implementation at leading cancer institutions. Building on this platform, Lumicell is investigating its fluorescence-guided imaging in gastrointestinal cancers, beginning with esophageal cancer.

Therapeutic: Surgery; Surgical Oncology

Thilo Hoelscher CEO

The technology from Memoire Medical (San Diego, California) is based on non-invasive transcranial mechanotransduction using ultrasound to activate endothelial Nitric Oxide Synthetase (eNOS) and expression of HSP70/90

Therapeutic: Neuromodulation-Neurostimulation

Michal Tavrovsky CCO

MenHealth (San Francisco, CA, USA) transforms urological diagnostics with an FDA-cleared, reimbursable mobile uroflowmetry platform. Using proprietary sound based technology, our app records accurate urinary flow curves and digital voiding diaries from patients testing at home. We eliminate invasive in-clinic testing, enabling providers to track conditions like benign prostatic hyperplasia (BPH), streamline practice workflows, and improve remote patient adherence before and after surgery.

Therapeutic: Urology; Remote Diagnostics; Remote Monitoring

Alan Lucas CEO

NaviSci (Brookline, MA) is capitalizing on the emergence of low-dose CT scanning to detect early-stage lung tumors and clinical studies demonstrating that surgical removal of less tissue in early-stage lung cancer, with appropriate margins, can be curative. The system integrates Augmented Reality (AR) and advanced software with surgical hardware to guide precise surgical resection by enabling, for the first time, real-time in vivo tissue measurement.

Therapeutic: Minimally invasive surgery; Surgical oncology

Robert Rennaker CEO

NeuWire Medical (Plano, Texas, USA) offers closed-loop, miniature, wireless vagus nerve stimulation designed to integrate recovery from stroke into daily life.

Therapeutic: Neuromodulation-Neurostimulation; Chronic ischemic stroke rehabilitation

Caitlin Cameron Chair & CEO

OtoNexus Medical Technologies (Bellevue, WA) is a medical device company developing innovative diagnostic solutions based on its proprietary through-air ultrasound technology platform. Headquartered in Bellevue, Washington, the company is advancing technologies designed to provide rapid, objective diagnostic information for the evaluation of middle ear disease. Focused on improving patient outcomes and supporting responsible antibiotic stewardship, OtoNexus is building a patented technology platform with potential applications across multiple medical and non-medical markets.

Therapeutic: Diagnostics

Adrian Mendes CEO

Perimeter Medical Imaging AI (Dallas, Texas) is advancing cancer surgery with high-resolution Optical Coherence Tomography (OCT) and proprietary AI. Approved by the FDA in March 2026, Perimeter Claire™ is the first AI-enabled 3D imaging platform built specifically for real-time breast cancer margin assessment during lumpectomy procedures. By providing 10x sharper resolution than standard X-ray or ultrasound and highlighting suspicious tissue in minutes, Claire™ gives surgeons cellular-level clarity to help remove all cancer in a single procedure.

Therapeutic: Oncology

Will Mauldin CEO

Rivanna Guidance Solutions (RGS) (Charlottesville, VA, USA) is transforming epidural placement with Accuro 3S, an FDA-cleared, AI-powered ultrasound system providing real-time anatomical and needle guidance. Epidurals still rely largely on touch, leaving patients vulnerable to repeated attempts, failed placements, and complications. Accuro 3S combines automated anatomy recognition, continuous needle tracking, and hands-free probe positioning to support precise placement. RGS targets an estimated $300 million initial market in labor and delivery within a broader $3.5 billion opportunity, advancing safer, more compassionate care for patients.

Therapeutic: Imaging; Pain Control

Stephen Belcher CEO

Secure Closure Inc. (Denver, Colorado, USA) is developing Quattro-Close™, a next-generation, suture-based large-bore vascular closure device for minimally invasive cardiovascular procedures including TAVR and EVAR. Designed as a single-device, over-the-wire solution, Quattro-Close combines four-point suture delivery with proprietary technology, including the Halo-Lock™ closure mechanism, to provide reliable, predictable closure, including in challenging anatomy. The technology aims to reduce bleeding complications, improve patient safety, simplify procedures, and lower healthcare costs.

Therapeutic category: Cardiovascular

Brian Cooley CEO

Sofusa Holdings (New York, NY) is building the future of precision lymphatic medicine. By enabling clinicians to both visualize and treat the lymphatic system, we aim to reveal biology, improve therapeutic precision, and transform the treatment of immune-mediated diseases. As a clinical-stage medical technology company, we have developed a proprietary platform that provides direct, continuous access to the lymphatic system. Human studies have demonstrated enhanced therapeutic activity in patients refractory to conventional biologic therapy, supporting new approaches to functional imaging and biologic treatment.

Therapeutic: Drug Delivery; Autoimmune; Oncology

Bret Boudousquie CEO

Stratus® Medical (Magnolia, Texas) is Advancing RF Technology for the Treatment of Pain®. The NIMBUS® RF Multitined Expandable Electrode is used in RF procedures for the treatment of pain. NIMBUS is used by 300+ leading US hospitals and has been utilized in >500K patient treatments. NIMBUS has 40+ issued patents, several patents pending, is FDA cleared and CE marked. Our differentiated multitined expandable design rapidly creates a large volume lesion that provides reproducible & durable pain relief, faster procedure times, and lower cost. We are leveraging the multitined design in the high growth bone ablation segment with our forthcoming neurovasis BVNA* & Stratus RF Generator* (*not FDA cleared). 

Therapeutic: Interventional; Interventional Pain Medicine

Elaine Horn-Ranney CEO

Tympanogen (Richmond, VA) offers ear, nose, and throat surgeons efficiency in their practice through thoughtfully designed solutions that fit existing clinical workflows. The flagship product, Perf-Fix Otologic Gel Patch, repairs chronic eardrum perforations without surgery. The Perf-Fix procedure can be performed during a short doctor visit without the need for sedation or anesthesia, even for children. Tympanogen is giving over 5 million patients who are avoiding surgery the opportunity to heal an irreversible, chronic medical issue.

Therapeutic: ENT